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Abstract: Background: Non-Celiac Wheat Sensitivity (NCWS) is still a largely undefined condition,
due to the lack of a diagnostic marker. Few data are available about the nutritional characteristics
of NCWS patients at diagnosis. Aims: To evaluate the proportion of NCWS patients who were
underweight, normal weight, overweight, or obese at diagnosis, and to search for possible correlations
between their Body Mass Index (BMI) and other NCWS-related disease characteristics. Patients and
Methods: The clinical charts of 145 NCWS patients (125 F, 20 M, mean age 37.1± 11.4 years), diagnosed
between January 2012 and March 2018, were reviewed. As a comparison, 84 celiac disease (CD)
patients (73 F, 11 M, mean age 39.8 ± 13.9 years) were evaluated. All NCWS diagnoses were based on a
double-blind placebo-controlled wheat challenge (DBPCWC) method. Results: BMI distribution was
similar in the NCWS (6.2% underweight and 15.2% obese subjects) and CD patients (6% underweight
and 7.1% obese subjects). Underweight NCWS subjects were significantly younger and had a shorter
clinical history than the overweight or obese ones. Unlike the other NCWS patients, none of them had
a DQ2 and/or DQ8 haplotype. Overweight and obese NCWS patients were more frequently suffering
from associated autoimmune diseases than the other BMI categories (P = 0.05). Compared to the CD
controls, NCWS patients showed a higher frequency of Irritable Bowel Syndrome (IBS)-like (P = 0.01)
and extraintestinal symptoms (P = 0.03) and a longer clinical history (P = 0.04), whereas weight loss
was more frequent in CD (P = 0.02). Conclusions: NCWS patients showed a BMI distribution similar
to CD patients. However, NCWS was found to be a heterogenous condition that regards BMI, and
clinical characteristics differed between the underweight and overweight/obese patients.
Keywords: non-celiac wheat sensitivity (NCWS); Body Mass Index (BMI); autoimmune diseases;
HLA haplotype; Celiac Disease (CD); Irritable Bowel Syndrome (IBS)
1. Introduction
In recent years, a new gluten- or wheat-related disease has emerged, a condition labelled
“non-celiac gluten sensitivity” (NCGS) or “non-celiac wheat sensitivity” (NCWS) [1,2]. It is very often
a self-reported condition, since patients refer to intestinal and extra-intestinal symptoms caused by
gluten and/or wheat ingestion, even though they do not have celiac disease (CD) or wheat allergy [1,3].
However, NCWS is a still largely undefined condition, much less widely known than CD, which
has been historically considered the main gluten-related disease. There are, at present, no diagnostic
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markers for NCWS, its pathogenesis is uncertain, and it is debated whether NCWS patients really
need to adhere to a strict gluten-free diet. CD is considered an autoimmune disease affecting both the
small bowel and extra-intestinal sites and is determined by gluten ingestion in genetically predisposed
persons who carry the Human Leukocyte Antigen (HLA)-DQ2 and/or -DQ8 haplotypes. By contrast,
very few data are available about NCWS pathogenesis; previous studies have suggested a prevalent
role for Fermentable Oligosaccharides-Disaccharides-Monosaccharides and Polyols (FODMAPs) [4]
while others have hypothesized the activation of innate immunity [5] or a non-IgE-mediated food
allergy [6].
Regarding diagnosis, patients with suspected CD can be evaluated by a combination of
immunoassays, which offer a very high sensitivity, since if IgA anti-transglutaminase and/or IgG
anti-Deamidate Gliadin Peptide assays are positive, then the test is considered positive for CD [7].
On the other hand, no biomarkers have been identified to date for NCWS.
Moreover, the clinical presentation, diarrhea, malabsorption, and malnutrition were formerly
considered the classical symptoms of CD, due to the presence of intestinal villi atrophy [8]. Nevertheless,
in the last few decades, the frequency of this typical clinical picture has progressively decreased, and
atypical manifestations have increased [9]. Indeed, many reports indicate that CD can be found in
normal or overweight subjects; hence, CD does not always present with malnutrition [10–15].
Finally, very few reports on NCWS have focused on nutritional status. In our experience, the
“self-reported NCWS patients” condition includes both patients who report weight loss and thinness
and others who report diffuse swelling, weight increase, and obesity, but all attribute their symptoms
to eating gluten.
In this retrospective study, we reviewed our database of adult patients with a definitive diagnosis
of NCWS based on a double-blind placebo-controlled wheat challenge (DBPCWC) method, to evaluate
the proportion of patients who were underweight, overweight, or obese at diagnosis, and to
search for possible correlations between their Body Mass Index (BMI) and other NCWS-related
disease characteristics.
2. Patients and Methods
The clinical charts of the NCWS patients attending the outpatient clinics of the Department of
Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine
of the Hospital of Sciacca (both in southern Italy) were reviewed with a retrospective method. They
had all been diagnosed with NCWS between January 2012 and March 2018. These charts included
specific sections for the clinical presentation of the disease, physical examination, biochemical features,
histological characteristics, and BMI. Incomplete clinical charts were excluded. A control group
was also selected, composed of CD patients randomly chosen by a computer-generated method
from subjects diagnosed during the same period, age- (±2 years) and sex-matched (±5%) with the
NCWS patients.
2.1. Non-Celiac Wheat Sensitivity Diagnosis
CD or wheat allergy diagnoses had been ruled out in all the study patients, according to the
following criteria:
(1) Negative serum assays for CD-anti-tissue transglutaminase (anti-tTG) IgA and anti-deamidated
gliadin peptides (anti-DGP) IgG antibodies; (2) the absence of intestinal villous atrophy, documented
in all the patients carrying the DQ2 and/or the DQ8 HLA haplotypes; (3) and negative IgE-mediated
immune-allergy tests to wheat (skin prick tests and/or specific serum IgE detection). Furthermore, the
criteria adopted in our patients, in accordance with our diagnostic protocol for NCWS diagnosis, were
a resolution of the symptoms on a standard elimination diet without wheat, cow’s milk, yeast, and
other food(s) causing self-reported symptoms, followed by symptom reappearance on a Double-Blind
Placebo-Controlled Wheat Challenge (DBPCWC), performed as described previously [16,17]. As in
previous studies, a double-blind placebo-controlled cow’s milk protein challenge and other open food
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challenges were also performed. Additional inclusion criteria were: age above 20 years, follow-up
duration longer than 12 months after the initial diagnosis, and at least two outpatient visits during the
follow-up period [16].
2.2. Celiac Disease Diagnosis
CD was diagnosed in the presence of positive serum anti-tTG and/or anti-DPG antibodies and
duodenal villous atrophy at histologic examination, followed by the resolution of symptoms after
commencement of the gluten-free diet. The above clinical investigations were always performed on a
diet containing gluten (at least eight grams per day) followed for a minimum of 4 weeks [18].
2.3. Outcomes
BMI was used in our study to define the nutritional status of the patients. The World Health
Organization (WHO) defines BMI < 18.5 as underweight, 18.5–24.9 as normal, 25.0–29.9 as overweight,
and 30 or over as obese [19]. As these criteria are only applicable above the age of 20, younger patients
were excluded. The BMI of the study patients was correlated with the following clinical and laboratory
parameters: (1) gender; (2) age at diagnosis; (3) coexistent atopic diseases (i.e., respiratory allergy or
atopic dermatitis); (4) coexistent autoimmune diseases; (5) the presence and kind of irritable bowel
syndrome (IBS)-like symptoms (i.e., diarrhea, constipation, or both, occurring at least 6 months before
diagnosis, and presenting during the previous 3 months); (6) the presence of functional dyspepsia,
defined as postprandial fullness, early satiety, epigastric pain, and epigastric burning severe enough to
interfere with usual activities and occurring at least 3 days per week over the previous 3 months, with
an onset of at least 6 months beforehand [20]; (7) the presence of extraintestinal symptoms (i.e., a foggy
brain, headache, fatigue, joint and muscle pain, leg or arm numbness); (8) the presence of weight loss;
(9) symptom duration; and (10) the presence/absence of DQ2/DQ8 HLA haplotypes.
2.4. Statistical Analysis
Data were expressed as mean ± standard deviation when the distribution was Gaussian, and
differences were calculated using Student’s t test. For variables with a non-Gaussian distribution,
values were expressed as median and range and analyzed with the Mann-Whitney U test. To evaluate
the correlation between the DQ2/DQ8 HLA haplotypes versus BMI score, the Spearman rank correlation
test was used. The Chi-square test or Fisher‘s Exact test were used to compare categorical variables.
3. Results
Over the study period, we selected the clinical charts of 145 NCWS patients, another 40 having
been excluded as they were incomplete; the NCWS study group, therefore, included 125 females and 20
males (mean age 37.1 ± 11.4 years). As a comparison, the clinical charts of 84 celiac patients (73 females,
11 males, mean age 39.8 ± 13.9 years) were evaluated.
3.1. BMI
Figure 1 shows the distribution of underweight, normal weight, overweight, and obese subjects in
the NCWS and CD patients included in the study. Among the NCWS patients, nine were underweight
(6.2%) and 22 obese (15.2%); the overall frequency of overweight plus obese NCWS patients was
37.9%. For the CD patients, five were underweight (6%) and six obese (7.1%); the overall percentage
of overweight plus obese CD patients was 28.5%. There were no statistically significant differences
between NCWS and CD patients for BMI distribution, even when overweight and obese patients were
considered as a single subgroup.
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Figure 1. Distribution of underweight, normal weight, overweight and obese subjects in the non-
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longer  in the overweight subjects than in normal subjects (P = 0.04). All the underweight NCWS pa-
tients were negative for HLA DQ2 or DQ8 haplotypes, whereas these haplotypes were present in 
about half of the patients in the other BMI categories (HLA DQ2/DQ8 frequency: underweight vs. 
normal, overweight, and obese, P= 0.003, 0.005, and 0.07, respectively). Furthermore, coexistent au-
toimmune diseases were more frequent in the obese than in normal weight NCWS subjects (P = 
0.05) 
Table 1. Correlations between Body Mass Index (BMI) and clinical and laboratory variables in 145 
NCWS patients. Values are given as an absolute number and as a percentage (in brackets) in the re-
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(Group 2, n = 82) 
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(Group 3, n = 32) 
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Sex (Female/Male) 7/2 70/12 29/3 19/3 
Age 30.4 ± 10.3 35.6 ± 12 39.7 ± 9.5 40.2 ± 10.8 
Atopic diseases 4 (44%) 34 (41%) 12 (38%) 8 (36%) 
Autoimmune diseases 2 (22%) 13 (16%) 6 (19%) 9 (41%) 
IBS-like presentation 8 (89%) 75 (92%) 32 (100%) 20 (91%) 
Diarrhea 4 (44%) 43 (52%) 17 (53%) 10 (45%) 
Constipation 1 (11%) 16 (20%) 8 (25%) 4 (18%) 
Alternate bowel 
movements 
3 (33%) 16 (19%) 5 (15%) 6 (27%) 
Functional 
dyspepsia 4 (44%) 40 (51%) 18 (56%) 13 (59%) 
Extraintestinal symptoms 7 (78%) 61 (74%) 27 (44%) 17 (77%) 
Weight loss 4 (44%) 17 (21%) 6 (19%) 3 (14%) 
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Table 2 compares the NCWS and CD patients in regard to the clinical variables evaluated in 
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3.2. Correlation of BMI with Clinical and Laboratory Parameters
Table 1 reports the correlations between BMI and the clinical and laboratory parameters in the
NCWS patients. Underweight subjects were significantly younger at diagnosis than the overweight or
obese subjects (underweight vs. overweight and obese, P = 0.04 and 0.03, respectively). Accordingly,
symptom duration was longer in the overweight and obese patients than in the underweight patients
(underweight vs. overweight and obese, P = 0.04 for both groups); the duration was also longer in
the overweight subjects than in normal subjects (P = 0.04). All the underweight NCWS patients were
negative for HLA DQ2 or DQ8 haplotypes, whereas these haplotypes were present in about half of the
patients in the other BMI categories (HLA DQ2/DQ8 frequency: underweight vs. normal, overweight,
and obese, P= 0.003, 0.005, and 0.07, respectively). Furthermore, coexistent autoimmune diseases were
more frequent in the obese than in normal weight NCWS subjects (P = 0.05).
Table 1. Correlations between Body Mass Index (BMI) and clinical and laboratory variables in 145
NCWS patients. Values are given as an absolute number and as a percentage (in brackets) in the
respective BMI subgroups.
BMI Score
Underweight
(Group 1, n = 9)
Normal Weight
(Group 2, n = 82)
Overweight
(Group 3, n = 32)
Obese
(Group 4, n = 22)
Sex (Female/Male) 7/2 70/12 29/3 19/3
Age 30.4 ± 10.3 35.6 ± 12 39.7 ± 9.5 40.2 ± 10.8
Atopic diseases (44%) 34 (41%) 12 (38%) 8 (36%)
Aut immune diseases 2 (22%) 1 (16 ) 6 (19%) 9 (41%)
IBS-like presentation 8 (89%) 75 (92 ) 32 (100 20 (91%)
Diarrhe 4 (44%) 43 (52 ) 17 (53%) 10 (45%)
Constip tion 1 (11%) 16 (20 ) 8 (25%) 4 (18%)
Alternate bowel
movements 3 (33%) 16 (19%) 5 (15%) 6 (27%)
Functional
dyspepsia 4 (44%) 40 (51%) 18 (56%) 13 (59%)
Extraintestinal symptoms 7 (78%) 61 (74%) 27 (44%) 17 (77%)
Weight loss 4 (44%) 17 (21 ) 6 (19%) 3 (14%)
Symptoms duration (median
and range in months) 96 (27–120) 92 (24–180) 125 (45–264) 120 (24–288)
DQ2/DQ8 HLA haplotypes
DQ2and DQ8
negative 9 (100%) 37 (45%) 15 (48%) 16 (73%)
DQ2-positive 0 29 (36%) 11 (35%) 4 (18%)
DQ8-positive 0 14 (17%) 6 (17%) 2 (9%)
DQ2/DQ8 positive 0 2 (2%) 0 0
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Table 2 compares the NCWS and CD patients in regard to the clinical variables evaluated in the
study, as well as their HLA status. NCWS patients showed a higher frequency of IBS-like symptoms
than CD subjects (P = 0.01), as an IBS-like clinical presentation was recorded in over 90% of cases; in
particular, IBS-constipation was significantly more frequent in NCWS than in CD patients (P = 0.03).
Furthermore, the frequency of extra-intestinal symptoms was higher in NCWS than in CD subjects
(P = 0.03). On the other hand, weight loss as a presenting symptom was significantly more frequent in
CD than in NCWS patients (P = 0.02). Symptoms duration was longer in NCWS than in CD patients
(P = 0.04). Finally, as expected, the HLA haplotypes DQ2 and/or DQ8 were significantly more present
in CD than in NCWS subjects (P < 0.001).
Table 2. Comparison of clinical variables frequency and HLA status in 145 patients suffering from
Non-Celiac Wheat Sensitivity (NCWS) and in 84 sex- and age-matched Celiac Disease (CD) patients,
chosen as controls.
NCWS (n = 145) CD (n = 84) P Value
Atopic diseases 58 (40%) 33 (39%) ns
Autoimmune diseases 30 (21%) 24 (28%) ns
IBS-like presentation 135 (93%) 65 (77%) 0.01
Diarrhea 74 (51%) 34 (40%) ns
Constipation 29 (20%) 7 (8%) 0.03
Alternate bowel movements 30 (21%) 24 (28%) ns
Functional dyspepsia 75 (52%) 45 (53%) ns
Extraintestinal symptoms 112 (77%) 52 (62%) 0.03
Weight loss 30 (21%) 33 (39%) 0.02
Symptoms duration (median and range in months) 120 (24–288) 73 (15–228) 0.04
BMI score
Underweight 9 (6%) 5 (6%) ns
Normal weight 82 (57%) 55 (65%) ns
Overweight 32 (22%) 18 (21%) ns
Obese 22 (15%) 6 (8%) ns
DQ2/DQ8 HLA
haplotypes
DQ2/DQ8 negative 77 (53%) 0
DQ2-positive 44 (30%) 72 (86%)
DQ8-positive 22 (15%) 8 (9%) <0.001
DQ2/DQ8 positive 2 (2%) 4 (5%)
4. Discussion
To our knowledge, this is the first study aiming to evaluate BMI in NCWS patients and its
correlation with other clinical and laboratory parameters, in comparison with a control group of
celiac patients.
More than one-third of the whole NCWS group of patients were overweight/obese, whereas
approximately 7% were underweight. Thus, in our study group, there was a high frequency of
overweight/obese NCWS patients. This frequency, however, is similar (albeit slightly lower) to the
percentage reported for the general Italian population; the Italian National Statistics Institute (ISTAT)
reported a frequency of 35% for overweight and 10% for obese subjects in people living in Italy [21].
The same report indicated a lower frequency of underweight subjects (3%) than we observed in our
NCWS group (7%) [21].
Multiple factors could influence the nutritional status of NCWS patients. One hypothesis is that,
since NCWS patients (most of them self-reporting their wheat-related symptoms) tend to choose to
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consume processed gluten-free foods, they could be following a diet including high levels of lipids
and sugars, and this, in turn, may put them at risk of becoming obese and developing metabolic
syndrome [22–24]. On the other hand, it has been demonstrated that when altering their dietary habits,
NCWS patients could experience a possible deficiency in macro and micronutrient intake due to dietary
self-restrictions, such as lower mean amounts of carbohydrates, proteins, fiber, polyunsaturated fatty
acids, calcium, and folates, (by avoiding fruit, vegetables, milk, and dairy products) when compared to
a control population [25,26]. To support this, in a previous study we demonstrated a high frequency of
osteopenia and osteoporosis in NCWS patients at diagnosis, which correlated with a tendency towards
a low BMI [26].
The results of the present study seem to indicate that the clinical characteristics of the
overweight/obese NCWS subjects and the underweight ones are different. Interestingly, overweight
and obesity in NCWS patients were associated with a longer clinical history and a higher frequency of
autoimmune diseases than in underweight subjects, respectively. In our study, the underweight NCWS
patients were diagnosed before the overweight and obese ones. In addition, symptom duration in the
overweight and obese NCWS patients was longer than in the underweight and normal ones. In other
words, the lower the BMI, the sooner the NCWS diagnosis was made, and the shorter the symptom
duration. A possible explanation could be that overweight and obese NCWS patients consult physicians
later than underweight ones and are, therefore, also diagnosed later. Being underweight is perhaps
self-perceived by patients as a more worrying clinical sign, pushing them to first consult a physician
and/or undergo a diagnostic work-up, which finally leads to a diagnosis and therapy (i.e., a gluten-free
diet). However, it cannot be ruled out that the clinical characteristics and BMI of the patients may
independently change with aging and with the progression of the disease (i.e., the appearance of
overweight and obese phenotypes). In addition, our data showed that overweight NCWS patients
present a higher association with autoimmune diseases, particularly autoimmune thyroiditis, than
normal weight subjects, and this disease is frequently complicated with hypothyroidism, which can
increase BMI values if not diagnosed or correctly treated [27]. We also found a statistically significant
difference between underweight NCWS patients and normal, overweight and obese ones in regards
to the HLA haplotypes: the percentage of DQ2/DQ8 positive patients in the normal and overweight
subgroups was in line (about 50%) with our and other authors’ previous data [1,16,28,29]. On the
contrary, all the underweight patients were DQ2/DQ8 negative, suggesting the hypothesis that these
patients have a different clinical condition and not a gluten-related disease. In particular, a coexistent
eating disorder in this subgroup of patients cannot be ruled out.
Data from the celiac patients included in this study were in agreement with previous research,
demonstrating the changes in the clinical presentation of the disease compared to the historical one
(i.e., malabsorption syndrome), with an increasing rate of non-classical and subclinical phenotypes [9].
Accordingly, overweight and obesity are being increasingly recognized in CD, with several papers
reporting from 8% to 40% of CD patients as overweight or even obese at diagnosis [10–15]. Our data
were in this range, as we found 8% subjects obese and 21% overweight.
As expected, the comparison between the NCWS and CD groups showed a somewhat longer
duration of clinical history in NCWS than in CD; this could be simply explained by the lack of a
diagnostic biomarker for NCWS. However, the median duration of symptoms before reaching the
NCWS and the CD diagnoses was far too long in both these diseases: the NCWS study patients
had a median of about 10 years of symptoms before diagnosis, with a maximum of over 20 years.
But it is noteworthy that the diagnostic delay was also long for CD, with a median of about 6 years
(73 months); this should be unacceptable for a well-known clinical condition for which there are
accurate serum markers.
Regarding the clinical presentation, there was a significantly higher frequency of IBS-like clinical
presentations in NCWS than in CD patients. More than 90% of NCWS patients showed IBS-like
symptoms, a result in agreement with many others in the literature, which underlines the overlap
between IBS and NCWS [30]. Interestingly, we found a higher frequency of IBS-constipation in
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NCWS (20%) than in CD patients (8%). Previous studies have investigated the efficacy of the
gluten-free/wheat-free diet in NCWS patients presenting with IBS-diarrhea [31,32], but our data seem
to suggest that IBS-constipation could also benefit from a gluten-free diet. Our NCWS study patients
also showed a higher frequency of extraintestinal symptoms (i.e., foggy mind, headache, fatigue, joint
and muscle pain, leg or arm numbness) than the CD patients; 77% of the NCWS study patients showed
extra-intestinal symptoms, and this could support the hypothesis that NCWS has an underlying
immunologic condition, which can determine a multi-organ dysfunction [33,34]. Obviously, DQ2-DQ8
haplotypes were more frequently observed in CD patients than in NCWS patients. However, we
confirmed that about 50% of NCWS patients had an HLA DQ2 and/or DQ8 haplotype, a frequency
higher than in the general population, and in agreement with previous reports [16].
Some limitations of our study must be underlined. Firstly, this is a retrospective study and the data
collection could be imprecise. Furthermore, we are unable to report other nutritional parameters apart
from BMI (i.e., levels of hemoglobin concentration, ferritin, albumin, vitamin B12, and serum folate).
We have no data on patients’ dietary habits, and our considerations about the factors associated with
underweight and overweight/obesity must be considered speculative. In the case of the underweight
NCWS patients, eating disorders were not regularly excluded by means of psychometric methods.
However, our study is the first to focus on BMI in NCWS patients and to attempt to correlate
the nutritional status of patients with the other clinical characteristics of this disease. Furthermore,
the major strength of the study is the patient selection process, based on an NCWS diagnosis made by
a rigorous DBPCWC protocol, over a six-year period.
In conclusion, our study suggests that, on the basis of our BMI findings, NCWS patients belong to
different populations, in keeping with the well-known heterogeneity of this condition. A quite large
subgroup of NCWS patients were overweight or obese and showed a longer clinical history and a higher
frequency of associated autoimmune diseases, especially autoimmune thyroiditis. A smaller subgroup,
including underweight subjects, had a shorter clinical history and was apparently characterized by a
lack of the DQ2/DQ8 haplotypes.
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